Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245997 · ClinicalTrials.gov registry record · Early Phase 1
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
A Early Phase 1 study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT02245997: Completed Early Phase 1 study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02245997 is a Early Phase 1 study of Neuroblastoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 78 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02245997, a Early Phase 1 study of Neuroblastoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to give 12T a smaller dose of radiation in order to decrease these late side effects.
Primary Outcome
will be assessed via imaging (CT+/- MRI and MIBG) and clinical evidence at the primary site post completion of treatment. The baseline scan will be the pre-irradiation CT scan. Local failure is defined as a relapse in the primary tumor bed or adjacent lymph nodes.
Conditions Studied
Interventions
- RADIATION External beam radiotherapy
- RADIATION proton beam RT
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2014-09 |
| Est. Completion | 2025-05-01 |
| Phase | Early Phase 1 |
What the finished NCT02245997 record still lists
NCT02245997 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 2 interventions - of which External beam radiotherapy is the first listed.
NCT02245997 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02245997 about?
NCT02245997 is a clinical study titled "Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma". The purpose of this study is to give 12T a smaller dose of radiation in order to decrease these late side effects.
What is the current status of trial NCT02245997?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 78 participants. The study started on 2014-09. Estimated completion is 2025-05-01.
What conditions does trial NCT02245997 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT02245997?
The interventions under investigation include: External beam radiotherapy (RADIATION), proton beam RT (RADIATION).
Who is sponsoring clinical trial NCT02245997?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02245997 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02245997's enrollment target sits among peer trials
78 38th of 94 higher than 57 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of N9 Chemotherapy in Children With Neuroblastoma
ACTIVE NOT RECRUITING · Early Phase 1
-
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
ACTIVE NOT RECRUITING · Early Phase 1
-
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia